{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:41:40Z","timestamp":1791290500969,"version":"4.3.0"},"reference-count":18,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2009,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>The objectives of this study were to evaluate emtricitabine (FTC) pharmacokinetics in pregnant women and their neonates and to determine the optimal prophylactic dose for neonates after birth to prevent mother-to-child transmission of human immunodeficiency virus (HIV). A total of 38 HIV-infected pregnant women were administered tenofovir disoproxyl fumarate (300 mg)-FTC (200 mg) tablets\u2014two tablets at the initiation of labor and one daily for 7 days postpartum. By pair, 11 maternal, one cord blood, and two neonatal FTC concentrations were measured using a high-performance liquid chromatography-tandem mass spectrometry validated method and analyzed by a population approach. Model and mean estimates (interpatient variability) were a two-compartment model for mothers, with an absorption rate constant of 0.54 h<jats:sup>\u22121<\/jats:sup>(61%), apparent elimination and intercompartmental clearances of 23.2 (17%) and 6.04 liters\u00b7h<jats:sup>\u22121<\/jats:sup>, and apparent central and peripheral volumes of 127 and 237 liters, respectively; an effect compartment linked to maternal circulation for cord blood and a neonatal compartment disconnected, after delivery, with a 10.6-h half-life (30%). After the 400-mg FTC administration, the median population area under the concentration-time curve and the minimal and maximal plasma FTC concentrations in pregnant women were 14.3 mg\u00b7liter<jats:sup>\u22121<\/jats:sup>\u00b7h and 1.68 and 0.076 mg\/liter, respectively. At delivery, median (range) predicted maternal and cord blood FTC concentrations were, respectively, 1.16 (0.14 to 1.99) and 0.72 (0.05 to 1.19) mg\u00b7liter<jats:sup>\u22121<\/jats:sup>. We concluded that the 400-mg FTC administration in pregnant women produces higher exposition than does the 200-mg administration in other adults, at steady state. FTC was shown to have good placental transfer (80%). Administering 1 mg FTC\/kg as soon as possible after birth or 2 mg\/kg 12 h after birth should produce neonatal concentrations comparable to the concentrations observed in adults.<\/jats:p>","DOI":"10.1128\/aac.00860-08","type":"journal-article","created":{"date-parts":[[2008,12,23]],"date-time":"2008-12-23T02:09:06Z","timestamp":1229998146000},"page":"1067-1073","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":55,"title":["Population Pharmacokinetics of Emtricitabine in Human Immunodeficiency Virus Type 1-Infected Pregnant Women and Their Neonates"],"prefix":"10.1128","volume":"53","author":[{"given":"De\u0301borah","family":"Hirt","sequence":"first","affiliation":[{"name":"EA3620, Universite\u0301 Paris\u2014Descartes, Paris, France"},{"name":"Unite\u0301 de Recherche Clinique, AP-HP, Ho\u0302pital Tarnier, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saik","family":"Urien","sequence":"additional","affiliation":[{"name":"EA3620, Universite\u0301 Paris\u2014Descartes, Paris, France"},{"name":"Unite\u0301 de Recherche Clinique, AP-HP, Ho\u0302pital Tarnier, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Rey","sequence":"additional","affiliation":[{"name":"Service de Pharmacologie Clinique, AP-HP, Ho\u0302pital Cochin-Saint-Vincent-de-Paul, Universite\u0301 Paris\u2014Descartes, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Arrive\u0301","sequence":"additional","affiliation":[{"name":"INSERM U897, ISPED, Universite\u0301 Victor Segalen, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier K.","family":"Ekoue\u0301vi","sequence":"additional","affiliation":[{"name":"Programme PAC-CI, ANRS Abidjan, Co\u0302te d'Ivoire"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Coffie\u0301","sequence":"additional","affiliation":[{"name":"Programme PAC-CI, ANRS Abidjan, Co\u0302te d'Ivoire"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sim Kruy","family":"Leang","sequence":"additional","affiliation":[{"name":"Service Gyne\u0301cologie-Obste\u0301trique de l'Ho\u0302pital Calmette, Phnom Penh, Cambodia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarita","family":"Lalsab","sequence":"additional","affiliation":[{"name":"Perinatal HIV Research Unit (PHRU), University of the Witwatersrand, Chris Hani Baragwanath Hospital, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divine","family":"Avit","sequence":"additional","affiliation":[{"name":"Programme PAC-CI, ANRS Abidjan, Co\u0302te d'Ivoire"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Nerrienet","sequence":"additional","affiliation":[{"name":"Institut Pasteur du Cambodge, Phnom Penh, Cambodia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"McIntyre","sequence":"additional","affiliation":[{"name":"Perinatal HIV Research Unit (PHRU), University of the Witwatersrand, Chris Hani Baragwanath Hospital, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ste\u0301phane","family":"Blanche","sequence":"additional","affiliation":[{"name":"Service d'Immunologie et He\u0301matologie Pe\u0301diatrique, Ho\u0302pital Necker Enfants Malades, Universite\u0301 Paris\u2014Descartes, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franc\u0327ois","family":"Dabis","sequence":"additional","affiliation":[{"name":"INSERM U897, ISPED, Universite\u0301 Victor Segalen, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Tre\u0301luyer","sequence":"additional","affiliation":[{"name":"EA3620, Universite\u0301 Paris\u2014Descartes, Paris, France"},{"name":"Unite\u0301 de Recherche Clinique, AP-HP, Ho\u0302pital Tarnier, Paris, France"},{"name":"Service de Pharmacologie Clinique, AP-HP, Ho\u0302pital Cochin-Saint-Vincent-de-Paul, Universite\u0301 Paris\u2014Descartes, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012299115260"},{"key":"e_1_3_2_3_2","unstructured":"NONMEM user's guide. 1998"},{"key":"e_1_3_2_4_2","unstructured":"629. Abstr. 15th Conf. Retrovir. Opportun. Infect. 2008"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270007300951"},{"key":"e_1_3_2_6_2","unstructured":"568. Abstr. 13th Conf. Retrovir. Opportun. Infect. 2006"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61605-5"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1086\/430764"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/10618600.1996.10474713","volume":"5","year":"1996","unstructured":"Ihaka, R., and R. Gentleman. 1996. R: a language for data analysis and graphics. J. Comput. Graph. Stat.5:299.","journal-title":"J. Comput. Graph. Stat."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200007280-00001"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0163-7258(80)90085-6"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jchromb.2008.02.008","volume":"865","year":"2008","unstructured":"Le Saux, T., S. Chhun, E. Rey, O. Launay, L. Weiss, J. P. Viard, G. Pons, and V. Jullien. 2008. Quantification of seven nucleoside\/nucleotide reverse transcriptase inhibitors in human plasma by high-performance liquid chromatography with tandem mass-spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.865:81-90.","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199733050-00002"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1749-6632.2000.tb05498.x","volume":"918","year":"2000","unstructured":"Mirochnick, M. 2000. Antiretroviral pharmacology in pregnant women and their newborns. Ann. N. Y. Acad. Sci.918:287-297.","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1970.tb03423.x"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/QAI.0b013e318050d88c","volume":"45","year":"2007","unstructured":"Ramanathan, S., G. Shen, A. Cheng, and B. P. Kearney. 2007. Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine\/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137. J. Acquir. Immune Defic. Syndr.45:274-279.","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1086\/315152"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.1.183-191.2004"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1177\/0091270007300808","volume":"47","year":"2007","unstructured":"Zhong, J., G. E. Chittick, L. H. Wang, J. Hui, J. A. Begley, and M. R. Blum. 2007. Pharmacokinetic evaluation of emtricitabine in combination with other nucleoside antivirals in healthy volunteers. J. Clin. Pharmacol.47:877-889.","journal-title":"J. Clin. Pharmacol."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00860-08","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00860-08","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T10:16:39Z","timestamp":1738836999000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00860-08"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["10.1128\/AAC.00860-08"],"URL":"https:\/\/doi.org\/10.1128\/aac.00860-08","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3]]},"assertion":[{"value":"2008-06-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2008-12-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-03-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}